An observational study in Coronary Artery Disease, sponsored by Istanbul University - Cerrahpasa. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Istanbul University - Cerrahpasa · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Coronary Artery Disease with a site in Turkey — 34 open to participants now, 43 under way, 4 of them phase 3. Coronary Artery Disease · Turkey.
Among the 139 studies in Coronary Artery Disease with a site in Turkey, this one is the 21st largest by planned enrollment of the 66 observational ones that give a count, is one of 18 that started in 2024, is one of 66 observational ones, reaches primary completion later than 20 of the 42 other live ones, and was the 96th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →34 of the 139 studies in Coronary Artery Disease with a site in Turkey are open now. Recruiting first, the newest first:
Adiyaman University · Sites in Turkey
Ages 18+
Elzem SEN · Sites in Turkey
Ages 18–80
Elzem SEN · Sites in Turkey
Ages 18–80
TC Erciyes University · Sites in Turkey
Ages 18–50 · Women only
Uludag University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 11 · Phase 4 1
First in 2004; this study’s year is marked. 18 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is close to the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 70 across the 73 interventional studies, 167 across the 66 observational. Of the 83 that completed or were terminated, 10 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 139 have an industry lead sponsor. The 10 most frequent:
Istanbul University - Cerrahpasa is the lead sponsor of 702 studies on the registry; 212 are open to participants now.
Istanbul University - Cerrahpasa has 5 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Coronary Artery Disease with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07444697Kırıkkale University"Erectile Function After PCI in MI and Non-MI Patients" | 2026-11 |
| NCT07051473Istanbul University - CerrahpasaRelationship Between Coronary CT Angiography Findings and Prognosis Of Patients Undergoing PCI | 2026-12 |
| NCT07825376Abant Izzet Baysal UniversityBranching Scenario-Based Education in Coronary Artery Disease | 2026-12 |
| NCT07771127Uludag UniversityHEMOSTATİC PAD AND SANDBAG | 2026-12-30 |
| NCT07841847Kutahya Health Sciences UniversityEffects of Personalized Cardiac Rehabilitation on miRNAs and Biochemical Biomarkers in Patients With Coronary Artery Disease | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 139 studies in Coronary Artery Disease with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers at Cerrahpaşa Medical School in Istanbul are studying how a heart imaging test called coronary CT angiography can help improve care for people with coronary artery disease. This disease happens when fatty buildups, known as plaques, form in the arteries that supply blood to the heart. Over time, these plaques can limit blood flow and lead to serious problems like heart attacks. The goal of this research is to better understand which types of plaques may lead to worse outcomes, and how treatment choices-such as placing a stent or using medication-can affect a person's long-term heart health. This study will help doctors make better treatment decisions in the future. Some plaques are more dangerous than others, even when they don't cause major blockages. These are called high-risk or "vulnerable" plaques. Even though they may not narrow the artery much at first, they can still cause heart attacks in the future. Currently, doctors do not usually place stents in arteries unless the plaque causes a serious blockage. This is because stenting also carries risks, and it is not clear whether treating high-risk plaques early-before they cause problems-helps people live longer or feel better. This study hopes to find out whether certain types of plaques should be treated differently in the future. This study will include at least 789 adults who have already had coronary CT angiography as part of their regular care at Cerrahpaşa Medical School's cardiology clinic. These participants were treated either with a stent or with medication, depending on their medical needs. The decision to do the scan and how to treat the person was made by their doctor, following national and international medical guidelines. People who join the study do so voluntarily. They can choose to leave the study at any time without affecting their regular medical care. Participants will be followed for at least one year, starting from the day of their CT scan. They will return for check-ups at 3, 6, and 12 months. After the first year, they will continue to have yearly follow-up visits as part of routine care. At each visit, the study team will check symptoms, such as chest pain or shortness of breath; monitor health indicators, like cholesterol and blood sugar; and review any new heart procedures or treatments. Researchers will also review results from medical tests, such as blood tests, electrocardiograms (EKGs), heart ultrasounds (echocardiograms), repeat heart scans or procedures if done. If a participant has had a heart procedure done at another hospital, they will be asked to bring those records to their next appointment. This helps the research team get a full picture of each participant's heart health. The researchers will look at the features of the plaques seen in each participant's heart scan. They want to find out which types of plaques are more likely to lead to heart attacks or other serious problems. Participants will be divided into groups based on whether they received a stent or not. The researchers will compare outcomes between these groups to see if certain plaque types are more dangerous and whether stenting made a difference. The study will try to answer questions like: which plaque features are linked to future heart problems; do people with high-risk plaques do better with stents or with medication; can doctors use plaque features to decide who should get a stent? This research may help doctors better identify high-risk plaques and choose the right treatment for each person. The study does not involve any new, experimental, or unapproved treatments. All participants will receive medical care that follows well-established guidelines from groups like the European Society of Cardiology (ESC) and the American Heart Association (AHA). Participants are not asked to take new medications or undergo any tests or treatments that are not already part of their usual care. If new medical knowledge becomes available during the study that could affect treatment, participants will be informed and can choose whether to continue with the original plan or make changes. All personal and medical information will be kept confidential. The data will be stored securely in the hospital's system, and only the research team and authorised health officials will be allowed to access it. Participants' names and other identifying information will not appear in any published reports. If a participant wants to know their results or the overall results of the study, they can ask for a report. Even if someone leaves the study or stops coming to the clinic, the information already collected may still be used in the research unless the participant requests otherwise. There is no cost to participate in this study. The study will not affect your health insurance or create any additional charges. All medical care will continue to be covered by Turkey's national health system or your existing insurance.
The study population consists of individuals residing in the Republic of Turkey. The study sample was selected using a simple random sampling method and includes individuals from this population who presented to the Cardiology Department of Cerrahpaşa Medical Faculty with symptoms or findings suggestive of stable coronary artery disease. It is assumed that every citizen living within the borders of the Republic of Turkey has an equal probability of presenting to the clinic with complaints related to this condition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In addition, meet at least one of the following conditions:
Exclusion Criteria:
The people that has at least one lesion in their coronary arteries, carrying at least one high-risk plaque feature, derived from CCTA and treated with PCI of that lesion
The people that has at least one lesion in their coronary arteries, carrying at least one high-risk plaque feature, derived from CCTA and not treated with PCI of that lesion
The people that has no lesion in their coronary arteries, carrying at least one high-risk plaque feature, derived from CCTA and treated with PCI of any lesion
All cause death
Death from any cause
Time frame: Baseline, 3 months, 6 months, 12 months
Major adverse cardiovascular events
Composition of cardiac death, spontaneous myocardial infarction, target vessel myocardial infarction, target vessel revascularisation, target lesion revascularisation
Time frame: Baseline, 3 months, 6 months, 12 months
Any myocardial infarction
Any event of myocardial infarction defined by the "Fourth Universal Definition Of Myocardial Infarction"
Time frame: Baseline, 3 months, 6 months, 12 months
Any revascularisation procedure
Revascularisation by either percutaneous coronary intervention or coronary artery bypass grafting
Time frame: Baseline, 3 months, 6 months, 12 months
Target vessel non-target lesion revascularisation
Any lesion or revascularisation of a lesion in the target vessel other than the target lesion, respectively
Time frame: Baseline, 3 months, 6 months, 12 months
Non-target vessel revascularisation
Revascularisation of a vessel for which revascularisation is not attempted in the first place, or of one with no lesion with high-risk plaque characteristics.
Time frame: Baseline, 3 months, 6 months, 12 months
Improvement in angina class as defined by the Canadian Cardiovascular Society (CCS)
Any improvement in the angina class of the Canadian Cardiovascular Society (CCS) from a higher class to a lower class
Time frame: Baseline, 3 months, 6 months, 12 months
Procedural success
Achievement of \< 30 % residual diameter stenosis of the target lesion assessed by visual inspection or QCA and no in-hospital major adverse cardiac events (MACE, a composite of death, MI, or repeat coronary revascularisation of the target lesion).
Time frame: At the end of percutaneous coronary intervention procedure
Plan to share: Yes — All IPD collected throughout the trial
Supporting information: Study protocol, Informed consent form
Time frame: Starting from the publication of results and earning of the 1 year of publication
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 24 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istanbul University - Cerrahpasa →